메뉴 건너뛰기




Volumn 12, Issue 11, 2010, Pages 713-720

Therapeutic goals in the treatment of Fabry disease

(11)  Mehta, Atul a,l   West, Michael L b   Pintos Morell, Guillem c   Reisin, Ricardo d   Nicholls, Kathy e   Figuera, Luis E f   Parini, Rossella g   Carvalho, Luiz R h   Kampmann, Christoph i   Pastores, Gregory M j   Lidove, Olivier k  


Author keywords

agalsidase alfa; agalsidase beta; enzyme replacement therapy; Fabry disease; lysosomal storage disease; treatment goals

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; CARBAMAZEPINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHENYTOIN;

EID: 78649632339     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e3181f6e676     Document Type: Article
Times cited : (35)

References (104)
  • 2
  • 4
    • 33745280137 scopus 로고    scopus 로고
    • High incidence of later-onset Fabry disease revealed by newborn screening
    • Spada M, Pagliardini S, Yasuda M, et al. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 2006;79:31-40.
    • (2006) Am J Hum Genet , vol.79 , pp. 31-40
    • Spada, M.1    Pagliardini, S.2    Yasuda, M.3
  • 6
    • 0242487692 scopus 로고    scopus 로고
    • The early clinical phenotype of Fabry disease: A study on 35 European children and adolescents
    • Ries M, Ramaswami U, Parini R, et al. The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents. Eur J Pediatr 2003;162:767-772.
    • (2003) Eur J Pediatr , vol.162 , pp. 767-772
    • Ries, M.1    Ramaswami, U.2    Parini, R.3
  • 7
    • 29944437554 scopus 로고    scopus 로고
    • Clinical manifestations of Fabry disease in children: Data from the Fabry Outcome Survey
    • Ramaswami U, Whybra C, Parini R, et al. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr 2006;95:86-92.
    • (2006) Acta Paediatr , vol.95 , pp. 86-92
    • Ramaswami, U.1    Whybra, C.2    Parini, R.3
  • 8
    • 0036260323 scopus 로고    scopus 로고
    • Quality of life of patients with Fabry disease
    • Gold KF, Pastores GM, Botteman MF, et al. Quality of life of patients with Fabry disease. Qual Life Res 2002;11:317-327.
    • (2002) Qual Life Res , vol.11 , pp. 317-327
    • Gold, K.F.1    Pastores, G.M.2    Botteman, M.F.3
  • 9
    • 0036240872 scopus 로고    scopus 로고
    • Assessment of health-related quality-of-life in males with Anderson Fabry disease before therapeutic intervention
    • Miners AH, Holmes A, Sherr L, Jenkinson C, MacDermot KD. Assessment of health-related quality-of-life in males with Anderson Fabry disease before therapeutic intervention. Qual Life Res 2002;11:127-133.
    • (2002) Qual Life Res , vol.11 , pp. 127-133
    • Miners, A.H.1    Holmes, A.2    Sherr, L.3    Jenkinson, C.4    MacDermot, K.D.5
  • 10
    • 33746908556 scopus 로고    scopus 로고
    • Comparison of health-related quality of life between heterozygous women with Fabry disease, a healthy control population, and patients with other chronic disease
    • Street NJ, Yi MS, Bailey LA, Hopkin RJ. Comparison of health-related quality of life between heterozygous women with Fabry disease, a healthy control population, and patients with other chronic disease. Genet Med 2006;8:346-353.
    • (2006) Genet Med , vol.8 , pp. 346-353
    • Street, N.J.1    Yi, M.S.2    Bailey, L.A.3    Hopkin, R.J.4
  • 11
    • 0034766525 scopus 로고    scopus 로고
    • Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 98 hemizygous males
    • MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001;38:750-760. (Pubitemid 33032930)
    • (2001) Journal of Medical Genetics , vol.38 , Issue.11 , pp. 750-760
    • MacDermot, K.D.1    Holmes, A.2    Miners, A.H.3
  • 12
    • 0034754467 scopus 로고    scopus 로고
    • Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 60 obligate carrier females [1]
    • MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001;38:769-775. (Pubitemid 33032933)
    • (2001) Journal of Medical Genetics , vol.38 , Issue.11 , pp. 769-775
    • MacDermot, K.D.1    Holmes, A.2    Miners, A.H.3
  • 13
    • 0035667062 scopus 로고    scopus 로고
    • Anderson-Fabry disease: Clinical manifestations of disease in female heterozygotes
    • Whybra C, Kampmann C, Willers I, et al. Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis 2001;24:715-724.
    • (2001) J Inherit Metab Dis , vol.24 , pp. 715-724
    • Whybra, C.1    Kampmann, C.2    Willers, I.3
  • 14
    • 33846265851 scopus 로고    scopus 로고
    • Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life
    • Wang RY, Lelis A, Mirocha J, Wilcox WR. Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med 2007;9:34-45.
    • (2007) Genet Med , vol.9 , pp. 34-45
    • Wang, R.Y.1    Lelis, A.2    Mirocha, J.3    Wilcox, W.R.4
  • 15
    • 38049036770 scopus 로고    scopus 로고
    • Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry
    • Wilcox WR, Oliveira JP, Hopkin RJ, et al. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 2008;93:112-128.
    • (2008) Mol Genet Metab , vol.93 , pp. 112-128
    • Wilcox, W.R.1    Oliveira, J.P.2    Hopkin, R.J.3
  • 16
    • 12944265457 scopus 로고    scopus 로고
    • Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease
    • Schiffmann R, Murray GJ, Treco D, et al. Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci USA 2000;97:365-370.
    • (2000) Proc Natl Acad Sci USA , vol.97 , pp. 365-370
    • Schiffmann, R.1    Murray, G.J.2    Treco, D.3
  • 17
    • 0013192938 scopus 로고    scopus 로고
    • A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease
    • Lee K, Jin X, Zhang K, et al. A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology 2003;13:305-313.
    • (2003) Glycobiology , vol.13 , pp. 305-313
    • Lee, K.1    Jin, X.2    Zhang, K.3
  • 18
    • 33748746594 scopus 로고    scopus 로고
    • Fabry disease: Guidelines for the evaluation and management of multi-organ system involvement
    • Eng CM, Germain DP, Banikazemi M, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 2006;8:539-548.
    • (2006) Genet Med , vol.8 , pp. 539-548
    • Eng, C.M.1    Germain, D.P.2    Banikazemi, M.3
  • 19
    • 78649634506 scopus 로고    scopus 로고
    • Effects of enzyme replacement therapy in Fabry disease\a comprehensive review of the medical literature
    • Lidove O, West ML, Pintos-Morell G, et al. Effects of enzyme replacement therapy in Fabry disease\a comprehensive review of the medical literature. Genet Med 2010;12:668-679.
    • (2010) Genet Med , vol.12 , pp. 668-679
    • Lidove, O.1    West, M.L.2    Pintos-Morell, G.3
  • 20
    • 68049134975 scopus 로고    scopus 로고
    • A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease
    • Whybra C, Miebach E, Mengel E, et al. A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease. Genet Med 2009;11:441-449.
    • (2009) Genet Med , vol.11 , pp. 441-449
    • Whybra, C.1    Miebach, E.2    Mengel, E.3
  • 21
    • 31544456336 scopus 로고    scopus 로고
    • Long-term therapy with agalsidase alfa for Fabry disease: Safety and effects on renal function in a home infusion setting
    • Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 2006;21:345-354.
    • (2006) Nephrol Dial Transplant , vol.21 , pp. 345-354
    • Schiffmann, R.1    Ries, M.2    Timmons, M.3    Flaherty, J.T.4    Brady, R.O.5
  • 22
    • 3142554529 scopus 로고    scopus 로고
    • Long-term safety and efficacy of enzyme replacement therapy for Fabry disease
    • Wilcox WR, Banikazemi M, Guffon N, et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 2004;75:65-74.
    • (2004) Am J Hum Genet , vol.75 , pp. 65-74
    • Wilcox, W.R.1    Banikazemi, M.2    Guffon, N.3
  • 23
    • 33749067655 scopus 로고    scopus 로고
    • Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease
    • Ries M, Clarke JT, Whybra C, et al. Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics 2006;118:924-932.
    • (2006) Pediatrics , vol.118 , pp. 924-932
    • Ries, M.1    Clarke, J.T.2    Whybra, C.3
  • 24
    • 77950519422 scopus 로고    scopus 로고
    • Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease
    • 837.e1
    • Schiffmann R, Martin RA, Reimschisel T, et al. Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease. J Pediatr 2010;156:832-837, 837.e1.
    • J Pediatr 2010 , vol.156 , pp. 832-837
    • Schiffmann, R.1    Martin, R.A.2    Reimschisel, T.3
  • 25
    • 33750090709 scopus 로고    scopus 로고
    • The role of ceramide trihexoside (globotriaosylceramide) in the diagnosis and follow-up of the efficacy of treatment of Fabry disease: A review of the literature
    • Bekri S, Lidove O, Jaussaud R, Knebelmann B, Barbey F. The role of ceramide trihexoside (globotriaosylceramide) in the diagnosis and follow-up of the efficacy of treatment of Fabry disease: a review of the literature. Cardiovasc Hematol Agents Med Chem 2006;4:289-297.
    • (2006) Cardiovasc Hematol Agents Med Chem , vol.4 , pp. 289-297
    • Bekri, S.1    Lidove, O.2    Jaussaud, R.3    Knebelmann, B.4    Barbey, F.5
  • 26
    • 0036122659 scopus 로고    scopus 로고
    • Natural history of Fabry renal disease: Influence of-galactosidase A activity and genetic mutations on clinical course
    • Branton MH, Schiffmann R, Sabnis SG, et al. Natural history of Fabry renal disease: influence of-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 2002;81:122-138.
    • (2002) Medicine (Baltimore) , vol.81 , pp. 122-138
    • Branton, M.H.1    Schiffmann, R.2    Sabnis, S.G.3
  • 27
    • 65649096032 scopus 로고    scopus 로고
    • Agalsidase alfa and kidney dysfunction in Fabry disease
    • West M, Nicholls K, Mehta A, et al. Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol 2009;20:1132-1139.
    • (2009) J Am Soc Nephrol , vol.20 , pp. 1132-1139
    • West, M.1    Nicholls, K.2    Mehta, A.3
  • 28
    • 39749149610 scopus 로고    scopus 로고
    • Fabry nephropathy: 5 years of enzyme replacement therapy\a short review
    • Barbey F, Lidove O, Schwarting A. Fabry nephropathy: 5 years of enzyme replacement therapy\a short review. Nephrol Dial Transplant 2008;1:11-19.
    • (2008) Nephrol Dial Transplant , vol.1 , pp. 11-19
    • Barbey, F.1    Lidove, O.2    Schwarting, A.3
  • 29
    • 67651123138 scopus 로고    scopus 로고
    • Fabry disease: Progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy
    • Schiffmann R, Warnock DG, Banikazemi M, et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 2009;24: 2102-2111.
    • (2009) Nephrol Dial Transplant , vol.24 , pp. 2102-2111
    • Schiffmann, R.1    Warnock, D.G.2    Banikazemi, M.3
  • 30
    • 44449143398 scopus 로고    scopus 로고
    • Nephropathy in males and females with Fabry disease: Cross-sectional description of patients before treatment with enzyme replacement therapy
    • Ortiz A, Oliveira JP, Waldek S, Warnock DG, Cianciaruso B, Wanner C, Fabry Registry. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant 2008;23:1600-1607.
    • (2008) Nephrol Dial Transplant , vol.23 , pp. 1600-1607
    • Ortiz, A.1    Oliveira, J.P.2    Waldek, S.3    Warnock, D.G.4    Cianciaruso, B.5    Wanner, C.6    Fabry, Registry.7
  • 31
    • 12144287518 scopus 로고    scopus 로고
    • Fabry disease defined: Baseline clinical manifestations of 366 patients in the Fabry Outcome Survey
    • Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004;34:236-242.
    • (2004) Eur J Clin Invest , vol.34 , pp. 236-242
    • Mehta, A.1    Ricci, R.2    Widmer, U.3
  • 32
    • 34248190164 scopus 로고    scopus 로고
    • Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease
    • Germain DP, Waldek S, Banikazemi M, et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 2007;18:1547-1557.
    • (2007) J Am Soc Nephrol , vol.18 , pp. 1547-1557
    • Germain, D.P.1    Waldek, S.2    Banikazemi, M.3
  • 33
    • 33846908304 scopus 로고    scopus 로고
    • Agalsidase-beta therapy for advanced Fabry disease: A randomized trial
    • Banikazemi M, Bultas J, Waldek S, et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 2007;146: 77-86.
    • (2007) Ann Intern Med , vol.146 , pp. 77-86
    • Banikazemi, M.1    Bultas, J.2    Waldek, S.3
  • 34
    • 34548474768 scopus 로고    scopus 로고
    • Antiproteinuric therapy and Fabry nephropathy: Sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta
    • Tahir H, Jackson LL, Warnock DG. Antiproteinuric therapy and Fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. J Am Soc Nephrol 2007; 18:2609-2617.
    • (2007) J Am Soc Nephrol , vol.18 , pp. 2609-2617
    • Tahir, H.1    Jackson, L.L.2    Warnock, D.G.3
  • 35
    • 0033574249 scopus 로고    scopus 로고
    • A more accurate method to estimate glomerular filtration rate from serum creati-nine: A new prediction equation. Modification of Diet in Renal Disease Study Group
    • Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creati-nine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-470.
    • (1999) Ann Intern Med , vol.130 , pp. 461-470
    • Levey, A.S.1    Bosch, J.P.2    Lewis, J.B.3    Greene, T.4    Rogers, N.5    Roth, D.6
  • 36
    • 0017195506 scopus 로고
    • A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine
    • Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976;58:259-263.
    • (1976) Pediatrics , vol.58 , pp. 259-263
    • Schwartz, G.J.1    Haycock, G.B.2    Edelmann Jr., C.M.3    Spitzer, A.4
  • 37
    • 77951692787 scopus 로고    scopus 로고
    • Monitoring renal function in children with Fabry disease: Comparisons of measured and creatinine-based estimated glomerular filtration rate
    • Tondel C, Ramaswami U, Aakre KM, Wijburg F, Bouwman M, Svarstad E. Monitoring renal function in children with Fabry disease: comparisons of measured and creatinine-based estimated glomerular filtration rate. Nephrol Dial Transplant 2010;25:1507-1513.
    • (2010) Nephrol Dial Transplant , vol.25 , pp. 1507-1513
    • Tondel, C.1    Ramaswami, U.2    Aakre, K.M.3    Wijburg, F.4    Bouwman, M.5    Svarstad, E.6
  • 38
    • 62149125881 scopus 로고    scopus 로고
    • New equations to estimate GFR in children with CKD
    • Schwartz GJ, Munoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009;20:629-637.
    • (2009) J Am Soc Nephrol , vol.20 , pp. 629-637
    • Schwartz, G.J.1    Munoz, A.2    Schneider, M.F.3
  • 39
  • 40
    • 0037038234 scopus 로고    scopus 로고
    • Clinical practice. Nondiabetic kidney disease
    • Levey AS. Clinical practice. Nondiabetic kidney disease. N Engl J Med 2002;347:1505-1511.
    • (2002) N Engl J Med , vol.347 , pp. 1505-1511
    • Levey, A.S.1
  • 42
    • 55749096248 scopus 로고    scopus 로고
    • Onset and progression of the Anderson-Fabry disease related cardiomyopathy
    • Kampmann C, Linhart A, Baehner F, et al. Onset and progression of the Anderson-Fabry disease related cardiomyopathy. Int J Cardiol 2008;130: 367-373.
    • (2008) Int J Cardiol , vol.130 , pp. 367-373
    • Kampmann, C.1    Linhart, A.2    Baehner, F.3
  • 43
    • 33947687663 scopus 로고    scopus 로고
    • Fabry disease: Baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry
    • Eng CM, Fletcher J, Wilcox WR, et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 2007;30:184-192.
    • (2007) J Inherit Metab Dis , vol.30 , pp. 184-192
    • Eng, C.M.1    Fletcher, J.2    Wilcox, W.R.3
  • 44
    • 34548316207 scopus 로고    scopus 로고
    • Cardiac manifestations of Anderson-Fabry disease: Results from the international Fabry outcome survey
    • Linhart A, Kampmann C, Zamorano JL, et al. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J 2007;28:1228-1235.
    • (2007) Eur Heart J , vol.28 , pp. 1228-1235
    • Linhart, A.1    Kampmann, C.2    Zamorano, J.L.3
  • 46
    • 61349177862 scopus 로고    scopus 로고
    • Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: Evidence for a better outcome with early treatment
    • Weidemann F, Niemann M, Breunig F, et al. Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 2009;119:524-529.
    • (2009) Circulation , vol.119 , pp. 524-529
    • Weidemann, F.1    Niemann, M.2    Breunig, F.3
  • 47
    • 33646173913 scopus 로고    scopus 로고
    • Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy
    • Beer M, Weidemann F, Breunig F, et al. Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy. Am J Cardiol 2006;97:1515-1518.
    • (2006) Am J Cardiol , vol.97 , pp. 1515-1518
    • Beer, M.1    Weidemann, F.2    Breunig, F.3
  • 48
    • 68049129847 scopus 로고    scopus 로고
    • Natural course of Fabry disease: Changing pattern of causes of death in FOS\Fabry Outcome Survey
    • Mehta A, Clarke JT, Giugliani R, et al. Natural course of Fabry disease: changing pattern of causes of death in FOS\Fabry Outcome Survey. J Med Genet 2009;46:548-552.
    • (2009) J Med Genet , vol.46 , pp. 548-552
    • Mehta, A.1    Clarke, J.T.2    Giugliani, R.3
  • 49
    • 73849102063 scopus 로고    scopus 로고
    • Life expectancy and cause of death in males and females with Fabry disease: Findings from the Fabry Registry
    • Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med 2009;11:790-796.
    • (2009) Genet Med , vol.11 , pp. 790-796
    • Waldek, S.1    Patel, M.R.2    Banikazemi, M.3    Lemay, R.4    Lee, P.5
  • 50
    • 38749130497 scopus 로고    scopus 로고
    • Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: A randomized, double-blind, placebo-controlled clinical trial of agalsidase-alfa
    • Hughes DA, Elliott PM, Shah J, et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomized, double-blind, placebo-controlled clinical trial of agalsidase-alfa. Heart 2008;94:153-158.
    • (2008) Heart , vol.94 , pp. 153-158
    • Hughes, D.A.1    Elliott, P.M.2    Shah, J.3
  • 51
    • 72149112208 scopus 로고    scopus 로고
    • Effect of agalsi-dase alfa replacement therapy on Fabry disease-related hypertrophic car-diomyopathy: A 12-to 36-month, retrospective, blinded echocardiographic pooled analysis
    • Kampmann C, Linhart A, Devereux RB, Schiffmann R. Effect of agalsi-dase alfa replacement therapy on Fabry disease-related hypertrophic car-diomyopathy: a 12-to 36-month, retrospective, blinded echocardiographic pooled analysis. Clin Ther 2009;31:1966-1976.
    • (2009) Clin Ther , vol.31 , pp. 1966-1976
    • Kampmann, C.1    Linhart, A.2    Devereux, R.B.3    Schiffmann, R.4
  • 52
    • 71649111830 scopus 로고    scopus 로고
    • Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: An analysis of registry data
    • [Erratum in: Lancet 2010;375:200.]
    • Mehta A, Beck M, Elliott P, et al. Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet 2009;374:1986-1996. [Erratum in: Lancet 2010;375:200.]
    • (2009) Lancet , vol.374 , pp. 1986-1996
    • Mehta, A.1    Beck, M.2    Elliott, P.3
  • 53
    • 20544452974 scopus 로고    scopus 로고
    • Enzyme replacement therapy in Fabry disease patients undergoing dialysis: Effects on quality of life and organ involvement
    • Pisani A, Spinelli L, Sabbatini M, et al. Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement. Am J Kidney Dis 2005;46:120-127.
    • (2005) Am J Kidney Dis , vol.46 , pp. 120-127
    • Pisani, A.1    Spinelli, L.2    Sabbatini, M.3
  • 54
    • 33645694070 scopus 로고    scopus 로고
    • The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease
    • Kalliokoski RJ, Kantola I, Kalliokoski KK, et al. The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease. J Inherit Metab Dis 2006;29:112-118.
    • (2006) J Inherit Metab Dis , vol.29 , pp. 112-118
    • Kalliokoski, R.J.1    Kantola, I.2    Kalliokoski, K.K.3
  • 55
    • 33644524081 scopus 로고    scopus 로고
    • Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A
    • Elliott PM, Kindler H, Shah JS, et al. Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. Heart 2006;92:357-360.
    • (2006) Heart , vol.92 , pp. 357-360
    • Elliott, P.M.1    Kindler, H.2    Shah, J.S.3
  • 56
    • 0141765881 scopus 로고    scopus 로고
    • Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: A prospective strain rate imaging study
    • Weidemann F, Breunig F, Beer M, et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 2003;108:1299-1301.
    • (2003) Circulation , vol.108 , pp. 1299-1301
    • Weidemann, F.1    Breunig, F.2    Beer, M.3
  • 57
    • 4344713083 scopus 로고    scopus 로고
    • Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease
    • Spinelli L, Pisani A, Sabbatini M, et al. Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease. Clin Genet 2004;66:158-165.
    • (2004) Clin Genet , vol.66 , pp. 158-165
    • Spinelli, L.1    Pisani, A.2    Sabbatini, M.3
  • 58
    • 44949248124 scopus 로고    scopus 로고
    • Treatment of Fabry disease with different dosing regimens of agalsidase: Effects on antibody formation and GL-3
    • Vedder AC, Breunig F, Donker-Koopman WE, et al. Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. Mol Genet Metab 2008;94:319-325.
    • (2008) Mol Genet Metab , vol.94 , pp. 319-325
    • Vedder, A.C.1    Breunig, F.2    Donker-Koopman, W.E.3
  • 59
  • 60
    • 67649583702 scopus 로고    scopus 로고
    • Effects of enzyme replacement therapy in patients with Anderson-Fabry disease: A prospective long term cardiac magnetic resonance imaging study
    • Imbriaco M, Pisani A, Spinelli L, et al. Effects of enzyme replacement therapy in patients with Anderson-Fabry disease: a prospective long term cardiac magnetic resonance imaging study. Heart 2009;95:1103-1107.
    • (2009) Heart , vol.95 , pp. 1103-1107
    • Imbriaco, M.1    Pisani, A.2    Spinelli, L.3
  • 62
    • 58849151159 scopus 로고    scopus 로고
    • Clinical usefulness of tissue Doppler imaging in predicting preclinical Fabry cardiomyopathy
    • Toro R, Perez-Isla L, Doxastaquis G, et al. Clinical usefulness of tissue Doppler imaging in predicting preclinical Fabry cardiomyopathy. Int J Cardiol 2009;132:38-44.
    • (2009) Int J Cardiol , vol.132 , pp. 38-44
    • Toro, R.1    Perez-Isla, L.2    Doxastaquis, G.3
  • 63
    • 62449143800 scopus 로고    scopus 로고
    • Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: Natural history data from the Fabry registry
    • Sims K, Politei J, Banikazemi M, Lee P. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry registry. Stroke 2009;40:788-794.
    • (2009) Stroke , vol.40 , pp. 788-794
    • Sims, K.1    Politei, J.2    Banikazemi, M.3    Lee, P.4
  • 64
    • 27844440793 scopus 로고    scopus 로고
    • Prevalence of Fabry disease in patients with cryptogenic stroke: A prospective study
    • Rolfs A, Bottcher T, Zschiesche M, et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 2005;366: 1794-1796.
    • (2005) Lancet , vol.366 , pp. 1794-1796
    • Rolfs, A.1    Bottcher, T.2    Zschiesche, M.3
  • 65
    • 34249096872 scopus 로고    scopus 로고
    • Middelheim Fabry Study (MiFaS): A retrospective Belgian study on the prevalence of Fabry disease in young patients with cryptogenic stroke
    • Brouns R, Sheorajpanday R, Braxel E, et al. Middelheim Fabry Study (MiFaS): a retrospective Belgian study on the prevalence of Fabry disease in young patients with cryptogenic stroke. Clin Neurol Neurosurg 2007; 109:479-484.
    • (2007) Clin Neurol Neurosurg , vol.109 , pp. 479-484
    • Brouns, R.1    Sheorajpanday, R.2    Braxel, E.3
  • 66
    • 74049117508 scopus 로고    scopus 로고
    • Frequency of unrecognized Fabry disease among young European-American and African-American men with first ischemic stroke
    • Wozniak MA, Kittner SJ, Tuhrim S, et al. Frequency of unrecognized Fabry disease among young European-American and African-American men with first ischemic stroke. Stroke 2010;41:78-81.
    • (2010) Stroke , vol.41 , pp. 78-81
    • Wozniak, M.A.1    Kittner, S.J.2    Tuhrim, S.3
  • 68
    • 0013155111 scopus 로고    scopus 로고
    • Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease
    • Moore DF, Altarescu G, Herscovitch P, Schiffmann R. Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease. BMC Neurol 2002;2:4.
    • (2002) BMC Neurol , vol.2 , pp. 4
    • Moore, D.F.1    Altarescu, G.2    Herscovitch, P.3    Schiffmann, R.4
  • 69
    • 18244397953 scopus 로고    scopus 로고
    • Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement
    • Moore DF, Altarescu G, Ling GS, et al. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 2002;33:525-531.
    • (2002) Stroke , vol.33 , pp. 525-531
    • Moore, D.F.1    Altarescu, G.2    Ling, G.S.3
  • 70
    • 3042541869 scopus 로고    scopus 로고
    • Arterial wall properties and Womersley flow in Fabry disease
    • Moore DF, Altarescu G, Pursley R, et al. Arterial wall properties and Womersley flow in Fabry disease. BMC Cardiovasc Disord 2002;2:1.
    • (2002) BMC Cardiovasc Disord , vol.2 , pp. 1
    • Moore, D.F.1    Altarescu, G.2    Pursley, R.3
  • 71
    • 69449094722 scopus 로고    scopus 로고
    • Can we use statins to prevent stroke in Fabry disease?
    • Politei JM. Can we use statins to prevent stroke in Fabry disease? J Inherit Metab Dis 2009;32:481-487.
    • (2009) J Inherit Metab Dis , vol.32 , pp. 481-487
    • Politei, J.M.1
  • 72
    • 34250723911 scopus 로고    scopus 로고
    • Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy\a retrospective analysis from the Fabry Outcome Survey
    • Hoffmann B, Beck M, Sunder-Plassmann G, Borsini W, Ricci R, Mehta A, FOS European Investigators. Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy\a retrospective analysis from the Fabry Outcome Survey. Clin J Pain 2007;23:535-542.
    • (2007) Clin J Pain , vol.23 , pp. 535-542
    • Hoffmann, B.1    Beck, M.2    Sunder-Plassmann, G.3    Borsini, W.4    Ricci, R.5    Mehta, A.6
  • 73
    • 33847198320 scopus 로고    scopus 로고
    • Enzyme replacement therapy with agalsidase alfa in children with Fabry disease
    • Ramaswami U, Wendt S, Pintos-Morell G, et al. Enzyme replacement therapy with agalsidase alfa in children with Fabry disease. Acta Paediatr 2007;96:122-127.
    • (2007) Acta Paediatr , vol.96 , pp. 122-127
    • Ramaswami, U.1    Wendt, S.2    Pintos-Morell, G.3
  • 74
    • 55849108852 scopus 로고    scopus 로고
    • Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry
    • Hopkin RJ, Bissler J, Banikazemi M, et al. Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr Res 2008; 64:550-555.
    • (2008) Pediatr Res , vol.64 , pp. 550-555
    • Hopkin, R.J.1    Bissler, J.2    Banikazemi, M.3
  • 75
    • 70349616542 scopus 로고    scopus 로고
    • Fabry disease in children and the effects of enzyme replacement treatment
    • Pintos-Morell G, Beck M. Fabry disease in children and the effects of enzyme replacement treatment. Eur J Pediatr 2009;168:1355-1363.
    • (2009) Eur J Pediatr , vol.168 , pp. 1355-1363
    • Pintos-Morell, G.1    Beck, M.2
  • 76
    • 33748635800 scopus 로고    scopus 로고
    • A survey of the pain experienced by males and females with Fabry disease
    • Gibas AL, Klatt R, Johnson J, Clarke JT, Katz J. A survey of the pain experienced by males and females with Fabry disease. Pain Res Manag 2006;11:185-192.
    • (2006) Pain Res Manag , vol.11 , pp. 185-192
    • Gibas, A.L.1    Klatt, R.2    Johnson, J.3    Clarke, J.T.4    Katz, J.5
  • 77
    • 0035840844 scopus 로고    scopus 로고
    • Neuropathic pain in Anderson-Fabry disease: Pathology and therapeutic options
    • MacDermot J, MacDermot KD. Neuropathic pain in Anderson-Fabry disease: pathology and therapeutic options. Eur J Pharmacol 2001;429:121-125.
    • (2001) Eur J Pharmacol , vol.429 , pp. 121-125
    • MacDermot, J.1    MacDermot, K.D.2
  • 78
    • 0348149005 scopus 로고    scopus 로고
    • Enzyme replacement therapy in heterozygous females with Fabry disease: Results of a phase IIIB study
    • Baehner F, Kampmann C, Whybra C, Miebach E, Wiethoff CM, Beck M. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study. J Inherit Metab Dis 2003;26:617-627.
    • (2003) J Inherit Metab Dis , vol.26 , pp. 617-627
    • Baehner, F.1    Kampmann, C.2    Whybra, C.3    Miebach, E.4    Wiethoff, C.M.5    Beck, M.6
  • 79
    • 0035816007 scopus 로고    scopus 로고
    • Enzyme replacement therapy in Fabry disease: A randomized controlled trial
    • Schiffmann R, Kopp JB, Austin HA 3rd, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001;285:2743-2749.
    • (2001) JAMA , vol.285 , pp. 2743-2749
    • Schiffmann, R.1    Kopp, J.B.2    Austin III, H.A.3
  • 80
    • 15044357727 scopus 로고    scopus 로고
    • Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: Data from FOS (Fabry Outcome Survey)
    • FOS European Investigators.
    • Hoffmann B, Garcia de Lorenzo A, Mehta A, Beck M, Widmer U, Ricci R; FOS European Investigators. Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey). J Med Genet 2005;42:247-252.
    • (2005) J Med Genet , vol.42 , pp. 247-252
    • Hoffmann, B.1    Garcia De Lorenzo, A.2    Mehta, A.3    Beck, M.4    Widmer, U.5    Ricci, R.6
  • 81
    • 19944375153 scopus 로고    scopus 로고
    • Enzyme replacement therapy in Japanese Fabry disease patients: The results of a phase 2 bridging study
    • Eto Y, Ohashi T, Utsunomiya Y, et al. Enzyme replacement therapy in Japanese Fabry disease patients: the results of a phase 2 bridging study. J Inherit Metab Dis 2005;28:575-583.
    • (2005) J Inherit Metab Dis , vol.28 , pp. 575-583
    • Eto, Y.1    Ohashi, T.2    Utsunomiya, Y.3
  • 82
    • 0035811624 scopus 로고    scopus 로고
    • Safety and efficacy of recombinant human alpha-galactosidase A\replacement therapy in Fabry's disease
    • Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase A\replacement therapy in Fabry's disease. N Engl J Med 2001;345:9-16.
    • (2001) N Engl J Med , vol.345 , pp. 9-16
    • Eng, C.M.1    Guffon, N.2    Wilcox, W.R.3
  • 83
    • 0036984003 scopus 로고    scopus 로고
    • Pain assessment: The advantages of using pain scales in lysosomal storage diseases
    • Cleeland CS. Pain assessment: the advantages of using pain scales in lysosomal storage diseases. Acta Paediatr Suppl 2002;91:43-47.
    • (2002) Acta Paediatr Suppl , vol.91 , pp. 43-47
    • Cleeland, C.S.1
  • 84
    • 0344443401 scopus 로고    scopus 로고
    • Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease
    • Schiffmann R, Floeter MK, Dambrosia JM, et al. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve 2003;28:703-710.
    • (2003) Muscle Nerve , vol.28 , pp. 703-710
    • Schiffmann, R.1    Floeter, M.K.2    Dambrosia, J.M.3
  • 85
    • 33747191418 scopus 로고    scopus 로고
    • Hyperhidrosis: A new and often early symptom in Fabry disease. International experience and data from the Fabry Outcome Survey
    • Lidove O, Ramaswami U, Jaussaud R, et al. Hyperhidrosis: a new and often early symptom in Fabry disease. International experience and data from the Fabry Outcome Survey. Int J Clin Pract 2006;60:1053-1059.
    • (2006) Int J Clin Pract , vol.60 , pp. 1053-1059
    • Lidove, O.1    Ramaswami, U.2    Jaussaud, R.3
  • 86
    • 65649098378 scopus 로고    scopus 로고
    • Reliability of quantitative sudo-motor axon reflex testing and quantitative sensory testing in neuropathy of impaired glucose regulation
    • Peltier A, Smith AG, Russell JW, et al. Reliability of quantitative sudo-motor axon reflex testing and quantitative sensory testing in neuropathy of impaired glucose regulation. Muscle Nerve 2009;39:529-535.
    • (2009) Muscle Nerve , vol.39 , pp. 529-535
    • Peltier, A.1    Smith, A.G.2    Russell, J.W.3
  • 87
    • 36549009001 scopus 로고    scopus 로고
    • Gastrointestinal symptoms in 342 patients with Fabry disease: Prevalence and response to enzyme replacement therapy
    • Hoffmann B, Schwarz M, Mehta A, Keshav S. Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Clin Gastroenterol Hepatol 2007;5:1447-1453.
    • (2007) Clin Gastroenterol Hepatol , vol.5 , pp. 1447-1453
    • Hoffmann, B.1    Schwarz, M.2    Mehta, A.3    Keshav, S.4
  • 89
    • 23044513293 scopus 로고    scopus 로고
    • Gastrointestinal manifestations of Fabry disease: Clinical response to enzyme replacement therapy
    • Banikazemi M, Ullman T, Desnick RJ. Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy. Mol Genet Metab 2005;85:255-259.
    • (2005) Mol Genet Metab , vol.85 , pp. 255-259
    • Banikazemi, M.1    Ullman, T.2    Desnick, R.J.3
  • 90
    • 40849094670 scopus 로고    scopus 로고
    • Safety and efficacy of enzyme replacement therapy with agalsidase beta: An international, open-label study in pediatric patients with Fabry disease
    • Wraith JE, Tylki-Szymanska A, Guffon N, et al. Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease. J Pediatr 2008;152: 563-570.
    • (2008) J Pediatr , vol.152 , pp. 563-570
    • Wraith, J.E.1    Tylki-Szymanska, A.2    Guffon, N.3
  • 94
    • 11144358101 scopus 로고    scopus 로고
    • The Mainz Severity Score Index: A new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy
    • Whybra C, Kampmann C, Krummenauer F, et al. The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 2004;65:299-307.
    • (2004) Clin Genet , vol.65 , pp. 299-307
    • Whybra, C.1    Kampmann, C.2    Krummenauer, F.3
  • 95
    • 76549116109 scopus 로고    scopus 로고
    • A validated disease severity scoring system for Fabry disease
    • Giannini EH, Mehta AB, Hilz MJ, et al. A validated disease severity scoring system for Fabry disease. Mol Genet Metab 2010;99:283-290.
    • (2010) Mol Genet Metab , vol.99 , pp. 283-290
    • Giannini, E.H.1    Mehta, A.B.2    Hilz, M.J.3
  • 96
    • 4744358540 scopus 로고    scopus 로고
    • Gaucher disease type 1: Revised recommendations on evaluations and monitoring for adult patients
    • Weinreb NJ, Aggio MC, Andersson HC, et al. Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Semin Hematol 2004;41:15-22.
    • (2004) Semin Hematol , vol.41 , pp. 15-22
    • Weinreb, N.J.1    Aggio, M.C.2    Andersson, H.C.3
  • 97
    • 4744370348 scopus 로고    scopus 로고
    • Therapeutic goals in the treatment of Gaucher disease
    • Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 2004;41:4-14.
    • (2004) Semin Hematol , vol.41 , pp. 4-14
    • Pastores, G.M.1    Weinreb, N.J.2    Aerts, H.3
  • 98
    • 9144251964 scopus 로고    scopus 로고
    • Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: Consensus recommendations
    • Charrow J, Andersson HC, Kaplan P, et al. Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. J Pediatr 2004;144:112-120.
    • (2004) J Pediatr , vol.144 , pp. 112-120
    • Charrow, J.1    Andersson, H.C.2    Kaplan, P.3
  • 100
    • 33747209013 scopus 로고    scopus 로고
    • A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)
    • Muenzer J, Wraith JE, Beck M, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 2006;8:465-473.
    • (2006) Genet Med , vol.8 , pp. 465-473
    • Muenzer, J.1    Wraith, J.E.2    Beck, M.3
  • 101
    • 70349187343 scopus 로고    scopus 로고
    • Guidelines to diagnosis and monitoring of Fabry disease and review of treatment experiences
    • Martins AM, D'Almeida V, Kyosen SO, et al. Guidelines to diagnosis and monitoring of Fabry disease and review of treatment experiences. J Pediatr 2009;155:S19-S31.
    • (2009) J Pediatr , vol.155
    • Martins, A.M.1    D'Almeida, V.2    Kyosen, S.O.3
  • 104
    • 34347260990 scopus 로고    scopus 로고
    • Fabry disease: Proposed guidelines from a French expert group for its diagnosis treatment and follow-up
    • Lidove O, Bekri S, Goizet C, et al. [Fabry disease: proposed guidelines from a French expert group for its diagnosis, treatment and follow-up.] Presse Med 2007;36:1084-1097.
    • (2007) Presse Med , vol.36 , pp. 1084-1097
    • Lidove, O.1    Bekri, S.2    Goizet, C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.